Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Health Reform Should 'Permanently Exclude' Funding Of Abortion Coverage, Family Research President Perkins Writes
"No matter what form of health care reform emerges from the current debates and discussion," Congress should include a "provision to the legislation to permanently exclude abortion from taxpayer-funded health care or health insurance," Family Research Council President Tony Perkins writes in a Politico opinion piece. Although some argue that the government "cannot or should not restrict benefits when it purchases insurance, the same way it does when reimbursing directly for medical procedures," that argument "already failed when it came up in the 1990s in the context of Medicaid managed care plans," Perkins writes, adding that the Hyde Amendment was "revised to cover them, as well." There also are arguments in Congress that "if people can opt for private health insurance that funds abortion and receive a tax break for their purchase of such insurance, then poor people dependent on direct government payments for their health insurance cannot be denied similar coverage," according to Perkins. However, "this presumes that there is no difference between what people may do with their own money and what they may do with the taxpayers" money," Perkins writes, adding that such an argument "makes sense only if we assume it"s all the government"s money in the end" (Perkins, Politico, 7/28).
generic viagra online
Non Invasive Assessment Of Treatment For Common Type Of Breast Cancer
Non-invasive imaging can measure how well patients with the most common form of breast cancer - estrogen receptor positive type - respond to standard aromatase inhibitor therapy after only two weeks and shows similar findings that more invasive needle sampling identifies, according to a poster presentation to be presented at the ASCO annual meeting May 29 - June 2, 2009, Orland, Fl.
News of the day
Advance Toward New Drugs That Turn Genes On And Off
Scientists in Michigan and California are reporting an advance toward development of a new generation of drugs that treat disease by orchestrating how genes in the body produce proteins involved in arthritis, cancer and a range of other disorders. Acting like an "on-off switch," the medications might ratchet up the production of proteins in genes working at abnormally low levels or shut off genes producing an abnormal protein linked to disease. Their report is in the current issue of ACS Chemical Biology, a monthly journal.
Diagnostics

Celsion And Yakult Honsha Announce Start-up Of Japanese Clinical Trial Sites In Celsion's Global Phase III ThermoDox(R) Trial For Primary Liver Cancer

Celsion Corporation (NASDAQ: CLSN) and Yakult Honsha Co., Ltd. (Tokyo: 2267) announced that Celsion"s global Phase III ThermoDox trial for the treatment of primary liver cancer will be extended to Japan by Yakult"s expertise. This is an important step towards a potential application to market the drug in Japan. Yakult Honsha is the exclusive licensor of Celsion"s ThermoDox in Japan. "We are proud to announce that Yakult will initiate trial sites and begin patient enrollment in Japan for our Phase III liver cancer trial, and we look forward to working with Yakult," stated Michael H. Tardugno, President and Chief Executive Officer. "The extension of our PIII study to Japan will enable us to accelerate patient enrollment in the trial and has the potential to decrease the time to market in Japan." "Japan has the highest rate of liver cancer in industrialized countries," said Dr. Kiyoshi Terada, Head, Pharmaceutical Division/Senior Managing Director, Member of the Board of Yakult Honsha. "Given there are limited effective treatment options for these patients, we are pleased to have the opportunity to provide ThermoDox to them in the clinical trial setting," Under the license agreement between Celsion and Yakult, Yakult is financially responsible for the patients enrolled in clinical trials in the Japanese sites and all the data generated in Japan will be jointly owned by Celsion and Yakult and can be used by Celsion to support regulatory filings in territories outside of Japan. Additional information on Celsion"s Phase III ThermoDox trial for primary liver cancer can be found at http://www.clinicaltrials.gov/ About ThermoDox ThermoDox in combination with hyperthermia has the potential to provide local tumor control and improve quality of life. ThermoDox is a proprietary heat-activated liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a wide range of cancers including breast cancer. Localized mild hyperthermia (40-42 degrees Celsius) releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor. ThermoDox has also demonstrated evidence of efficacy in a Phase I study for primary liver cancer. Celsion has been granted FDA Orphan Drug designation for ThermoDox and is conducting a pivotal global Phase III study in primary liver cancer under a FDA Special Protocol Assessment. ThermoDox® is a registered trademark of Celsion Corporation About Primary Liver Cancer Primary liver cancer is one of the most deadly forms of cancer and ranks as the fifth most common solid tumor cancer. The incidence of primary liver cancer is approximately 20,000 cases per year in the United States and is rapidly growing worldwide at approximately 1,000,000 cases per year, due to the high prevalence of Hepatitis B and C in developing countries. The standard first line treatment for liver cancer is surgical resection of the tumor, however 80% to 90% of patients are ineligible for surgery. Radio frequency ablation (RFA) has increasingly become the standard of care for non-resectable liver tumors, but the treatment becomes less effective for larger tumors. There are few non-surgical therapeutic treatment options available as radiation therapy and chemotherapy are largely ineffective in the treatment of primary liver cancer. About Yakult Yakult is a leading Japanese company focused on the development and marketing of pharmaceuticals, foods, beverages, and cosmetics with an emerging presence in oncology. For more information on Yakult, visit: www.yakult.co.jp or view the following company profile: http://www.yakult.co.jp/english/pdf/profile2008-2009.pdf Celsion


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009